Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Implantation of Artiflex phakic IOL for high myopia: safety of the procedure

Poster Details

First Author: S. Galvez-Carvajal SPAIN

Co Author(s):                        

Abstract Details


Myopia´s medical treatment is contact lenses or spectacles. Myopia´s surgical treatment can be done by keratorrefractive laser surgery, refractive lensectomy or phakic intraocular lens (PIOL) implantation, depending on myopia´s grade and patients´age.


To evaluate the safety of phakic intraocular lens surgery for correction of high myopia.


Retrospective study of patients undergoing ocular surgery with PIOL Artiflex® . This study included 45 eyes ( 22 OD and 23 OS) implanted with Artiflex® lenses. The corneal endothelial cells count (CECC) were recorded before and 12 months after the surgery. The anterior chamber depth (ACD) and endothelium-lens distances (ELD) were also analyzed.


Regarding the CECC, we found that preoperative count was 2513.18 ± 408.41 cell/mm2 and at 12 months after surgery was 2522 ± 323.33 cell/mm2. There were no statistical differences when the results were compared (Wisconsin test; p= 0.254). The ACD measurement was 3.140 ± 0,264 microns. The nasal and temporal ELD were 1363.11 ± 241.97m and 1502.00 ± 222.27 microns, respectively.


PIOL is a safe option for high myopia treatment. Twelve months after implantation of the PIOL, there was no significant loss in CEDD and the ELD were within the normal limits. Preoperative assessment is critical for the safety of the surgical procedure.

Financial Disclosure:


Back to Poster listing